Neuropsychological Signs of Alzheimer’s Disease 8 Years Prior to Diagnosis

Nicole S. Schmidt, Kirsten I. Taylor, Nancy S. Foldi, Manfred Berres, and Andreas U. Monsch

Memory Clinic, Department of Geriatrics, University Hospital, Basel, Switzerland
Centre for Speech, Language and the Brain, Department of Experimental Psychology, University of Cambridge, Cambridge, UK
Department of Psychology, Queens College and The Graduate Center, City University of New York, NY, USA
Department of Mathematics & Technology, RheinAhrCampus, Remagen, Germany

Handling Associate Editor: Mark Bondi

Abstract. We investigated the earliest neuropsychological changes in Alzheimer’s disease (AD) by comparing the baseline performance of 29 individuals who subsequently developed AD, within all age of 7.91 ± 2.70 years with 29 pairwise-matched individuals who remained cognitively healthy (NC). We hypothesized that subtle, qualitative changes in cognition precede clinical AD by several years, and therefore examined subjective as well as standard quantitative measures of cognition, in addition to subjective estimates of mood and medical status. Participants were selected from the 825 members of the longitudinal BASEL study (BAsel Study on the ELderly), all of whom had been ApoE-genotyped and received comprehensive bi-annual neuropsychological assessments. Within 13 years, 29 were diagnosed with probable AD. Each individual who progressed to AD (AD-P) was pairwise matched to a NC participant based on age, education, demographic status, observation period, and, importantly, ApoE genotype. A regression analysis using the lasso technique identified which of 115 neuropsychological variables best discriminated baseline NC from baseline AD-P performance. This analysis yielded eleven neuropsychological variables that optimally discriminated the two groups (correct classification rate: 60.4%): 1) Intrusions and 2) response bias in verbal learning and memory tasks; 3) delayed figure recall; 4–6) three Wechsler Adult Intelligence Scale (WAIS) Block Design subtest variables; 7–8) number of errors and repetitions on letter fluency; and 9–11) self-report of memory problems, a feeling of sadness, and cardiac problems. These results suggest that the preclinical neuropsychological cascade to AD includes subtle but identifiable qualitative impairments in verbal and visual memory, visuospatial processing, error control, and subjective neuropsychological complaints.

Keywords: Aging, Alzheimer disease, depressive symptoms, mild cognitive impairment, neuropsychological tests

INTRODUCTION

The identification of patients in the earliest possible stages of Alzheimer’s disease (AD) is a prerequisite for the development and implementation of preventive and therapeutic treatments. This study focuses on the earliest changes in neuropsychological functioning in AD [1]. Importantly, we investigated not only standard, quantitative performance measures, but also subjective and qualitative measures of neuropsychological functioning [2, 3] and mood [4], which potentially accompany quantitative changes in episodic memory commonly considered to mark the beginning stages of AD [5].

Correspondence to: Dr. Andreas U. Monsch, Memory Clinic, Department of Geriatrics, University Hospital, Schanzenstrasse 55, 4031 Basel, Switzerland. Tel.: +41 265 31 93, Fax: +41 265 37 94, E-mail: andreas.monsch@unibas.ch.

ISSN 1387-2677/12/$27.50 © 2012 – IOS Press and the authors. All rights reserved
A number of large-scale longitudinal studies provide valuable information about the neuropsychological characteristics of very early stage AD. We summarized those studies which had (1) long observation periods, (2) at least three testing visits, and (3) which administered comprehensive neuropsychological test batteries (see Supplementary Table 1; available online: http://www.j-alz.com/issues/34/vol34-2.html?supplementarydata=10). As expected, all studies that assessed verbal episodic memory reported that it was the first or among the first cognitive functions to be affected in future AD patients. When assessed, some studies found that nonverbal episodic memory also declined first and in tandem with verbal episodic memory [6–9]. Some studies reported that frontal lobe functions (e.g., executive functioning as measured by the Trail Making Test B, and abstract reasoning abilities) deteriorated at the same assessment as episodic memory functions [6, 10–14], or at the visit following the documentation of episodic memory impairments [15, 16]. Several studies reported that semantic fluency, a common measure of semantic memory, was either among the first functions affected [6, 7, 9, 10, 12], or that it deteriorated several years following episodic memory dysfunction [8, 16, 17]. However, Amieva and colleagues [15] found that semantic fluency was the first cognitive function affected, two years prior to abstract reasoning impairments and three years prior to nonverbal episodic memory impairments. These findings were largely confirmed in a comprehensive meta-analysis by Backman et al. [18]. The authors found that the preclinical phase of the disease is characterized by impairments in episodic memory, executive functioning, and perceptual speed, while standard measures of verbal ability, visuospatial skills, and attention were only moderately impaired.

Several recent analyses from longitudinal studies on the earliest detectable changes in cognitive functioning in the preclinical phase of AD focused on ‘change’ or ‘inflection’ points in cognitive functioning, i.e., points in time when cognitive functioning in future AD patients declines faster than cognitive functioning of those who remain cognitively healthy [16, 19–21]. Analyses from both the Bronx Aging Study [19] and the Baltimore Longitudinal Study of Aging (BLSA) [16] found that episodic memory declined at similar rates, with change points 8 years and up to 15 years prior to diagnosis, respectively. However, Riley and colleagues [20] found faster rates of cognitive decline in semantic memory and visuospatial construction in future AD patients compared to individuals who remained cognitively healthy. Other studies have likewise reported change points in visuospatial functioning [21, 22] and semantic memory functioning [22]. Taken together, longitudinal studies of cognitive functioning in future AD patients suggest that bilateral medial and anterior temporal lobe as well as frontal lobe dysfunction underpin the earliest cognitive impairments in AD, consistent with the sites of beginning neurofibrillary pathology [23], and that these changes appear approximately seven years prior to diagnosis.

Early pathological changes in AD may be manifested in subtle, qualitative neuropsychological dysfunction, before quantitative impairments emerge [2]. While most longitudinal studies have not addressed this hypothesis, the neuropsychological literature has documented qualitative abnormalities in AD patients’ neuropsychological performance that represent potential candidates for qualitative preclinical markers. For example, intrusion errors in verbal episodic memory tests were significantly more frequent in AD patients than in normal controls [24], and were associated with low levels of choline acetyltransferase and large numbers of cortical senile plaques in an autopsy study [3]. AD patients’ verbal episodic memory performance is also characterized by poor recognition discriminability with an abnormally liberal response bias [25]. Finally, AD patients demonstrate a reduced error control as measured by an increased number of errors and repetitions on tasks such as verbal fluency [2]. Thus, the search for preclinical neuropsychological markers may benefit from including not only participants’ quantitative scores, but also qualitative performance measures that elaborate on how participants performed the task.

Other research suggests that changes in mood, especially depressive symptoms, may surface years before the diagnosis of dementia [26]. For example, more depressive symptoms were observed in patients in the preclinical stage of AD than in nondemented persons in the Kungsholmen Project [27]. In the Religious Orders Study, Wilson and colleagues [28] found that the number of depressive symptoms at baseline predicted future AD, and that risk for the disease increased by about 20% with each additional symptom of depression. The PAQUID (Personnes Agées QUID) study [29] also found that depressive symptomatology in men appeared prior to a diagnosis of dementia. However, Chen and colleagues [30] failed to confirm this temporal relationship in the Monongahela Valley Independent Elders Survey (MoVIES) study, and suggested that depressive symptoms co-occur with, rather than predate, cognitive symptoms associated with dementia. These findings suggest that the predictive utility
of depressive symptomatology, together with measures of cognitive functioning in AD, requires further investigation.

The predictive value of measures related to both cognition and mood, i.e., subjective cognitive complaints, may be associated with a higher risk to develop AD [31]. Reisberg and coworkers suggested that self-reported concerns may be a harbinger of further cognitive decline, i.e., that future AD patients may be aware of a decline in their cognitive functioning before it is manifested by poor neuropsychological test performance [32]. These measures may be especially important for very high-functioning individuals whose initial decline from a near ceiling performance level is often difficult to quantify with traditional normative datasets in which they are underrepresented. Indeed, based on the cognitive reserve hypothesis [33], high functioning individuals may have a different course of preclinical cognitive decline whereby the successful compensation of impairments is accompanied by an awareness that such compensation was necessary, i.e., a subjective awareness of cognitive difficulties without corresponding quantitative impairments on neuropsychological testing.

The purpose of the present study was to determine the earliest neuropsychological changes in AD in members of the Basel Study on the Elderly (BASEL study). This cohort has been followed bi-annually for up to 13 years with a medical screening questionnaire and comprehensive neuropsychological assessment addressing all major cognitive domains, mood and subjective measures of neuropsychological functioning, and medical status. We compared the baseline performance of 29 individuals who progressed to AD (AD-P) over the course of 8 years with 29 carefully matched individuals who had remained cognitively healthy within the same timeframe (normal control (NC) group). Since the emergence of AD is known to be influenced by demographic and genetic factors [34], most notably age, education, gender, and the presence of an ApoE4 allele, the AD-P and NC groups were pairwise matched on these variables. We compared baseline performance of the AD-P and the NC individuals on standard quantitative cognitive performance measures, and, critically, on qualitative measures of cognition, and subjective measures of cognition, mood, and medical status.

**MATERIALS AND METHODS**

Table 1

<table>
<thead>
<tr>
<th>Test Domains tested</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical background</td>
<td>7</td>
</tr>
<tr>
<td>Subjective memory complaints, history of falls, diabetes, stroke, smoking, alcohol dependency, other problems, family history of cognitive impairment</td>
<td></td>
</tr>
<tr>
<td>Mood</td>
<td>19</td>
</tr>
<tr>
<td>Questionnaire for the Diagnosis of Depression according to DSM-IV [36]</td>
<td></td>
</tr>
<tr>
<td>General abilities</td>
<td>2</td>
</tr>
<tr>
<td>Mini-Mental State Examination [61]</td>
<td></td>
</tr>
<tr>
<td>Psychomotor speed</td>
<td>1</td>
</tr>
<tr>
<td>Trail Making Test-A [62]</td>
<td></td>
</tr>
<tr>
<td>Attention</td>
<td>8</td>
</tr>
<tr>
<td>Computerized Test of Attention [63]</td>
<td></td>
</tr>
<tr>
<td>Memory</td>
<td>29</td>
</tr>
<tr>
<td>German version of the California Verbal Learning Test [64], CERAD [36] word list, CERAD Figures, delayed recall</td>
<td></td>
</tr>
<tr>
<td>Language</td>
<td>10</td>
</tr>
<tr>
<td>Boston Naming Test [65], 15 items, Boston Naming Test, 45 items [65], Wechsler Adult Intelligence Scale (WAIS-R), Vocabulary [48]</td>
<td></td>
</tr>
<tr>
<td>Executive functioning</td>
<td>9</td>
</tr>
<tr>
<td>Trail Making Test-B (TMT-B [62]), TMT-B/TMT-A ratio, Semantic and Phonemic fluency (animals/food, G-O-S/3-words) [68], Clock Drawing Test [69]</td>
<td></td>
</tr>
</tbody>
</table>

**Participants**

All participants were members of the Basel study which originated in 1959 with a cohort of circa 6,500 healthy individuals who were studied with respect to cardiovascular risk factors, similar to the Framingham study. In 1997 all available and willing participants were invited back to participate in a new study focusing on preclinical cognitive markers of AD (BASEL Study on the ELderly) [35]. Cognitive screening consisted of a medical history questionnaire, the Consortium to Establish a Registry for Alzheimer’s Disease - Neuropsychological Assessment Battery (CERAD-NAB, [36]), where cognitively healthy individuals were defined as those with z-scores \( \leq -1.96 \) on no more than one of the eleven CERAD-NAB variables, as well as ApoE-genotyping [37] and an interview with a significant other, when appropriate. All cognitively healthy individuals with at least one ApoE4 allele, and an age, education, and gender matched group of cognitively healthy, non-ApoE4 individuals (total \( n = 825 \)) were assessed bi-annually with a comprehensive neuropsychological battery (see Table 1), a medical interview,
and informant history. If any self- or informant reported concerns about a cognitive change, a referral was made to the Memory Clinic of the Basel University Hospital for additional examinations that included magnetic resonance imaging (MRI), medical assessment, and full blood and serum analyses. Between 1997 and 2010, 53 individuals developed dementia, of whom 29 (55%) were diagnosed with probable AD [38, 39]. This prevalence corresponds to an annual incidence rate of 0.5 per 100 person-years. Mayeux and Stern [40] described higher annual incidence rates of 1.7–3.2 per 100 person-years for comparably aged individuals. The relatively low incidence rate in the present sample may be due to the stringent cognitive and neurologic inclusion criteria employed, which ensured the inclusion of optimally (as opposed to typically) aging individuals.

Each of the 29 AD-P individuals was matched to one NC individual. The NC group represents a highly robust normative sample [41], and all NC participants even remain healthy to date. All cognitive measures were available as standardized z-scores which were corrected for age, gender, and education. Since demographically-adjusted z-scores were not available for all clinical variables, the AD-P and NC groups were additionally pairwise matched according to the following criteria: 1) the length of the observation period, 2) gender, 3) age (±4 years), 4) education (±4 years) and (5) presence of at least one ApoE ε4 allele. As expected, the groups did not differ with respect to any of these variables or baseline Mini-Mental State Exam (MMSE) score (Table 2).

Moreover, the selected individuals (n = 58) did not differ from the original cohort (n = 825) with respect to MMSE score (t (820) = 0.500, p = 0.61) or gender (χ² (1, n = 825) = 0.306, p = 0.6). However, participants in the present study differed marginally from the entire cohort with respect to education (12.8 y versus 12.1 y, respectively; t (823) = 0.831, p = 0.065) and were on average 4.48 years older (t (823) = 6.609, p = 0.0001). This study was approved by the local Ethics Committee of Both Basels. All participants gave written informed consent after receiving information on the study, according to the Declaration of Helsinki.

Statistical analyses

Baseline data from the two groups were submitted to statistical analyses (Table 1, Supplementary Table 2). As the total number of variables (k = 115) outnumbered the number of participants in each group (n = 29), the "lasso" (least absolute shrinkage and selection operator) technique [42] for regression analysis was used to identify those variables that best discriminated between the two groups. The lasso method yields estimates of the regression coefficients, but not their standard errors, and minimizes the sums of squares of the residuals under the constraint that the sum of the absolute coefficients, also known as L1 norm, is restricted to: L1 = ∑ |βi| ≤ t. Bound t regulates the amount of shrinkage and the coefficients of some variables are shrunk to zero. Let t0 be the maximal sum of the absolute coefficients of the full model without shrinkage, and s = t0/t the amount of shrinkage. Smaller s's are associated with a greater shrinkage of coefficients and stricter variable selection. The optimal amount of shrinkage is determined by a 10-fold cross-validation, i.e., the sample is randomly split into ten subsamples, and each subsample is predicted by a model estimated from the other nine subsamples, where the optimization criterion is the correct classification rate (CCR). The lasso method combines the advantages of subset selection (i.e., good interpretability by selecting covariates with a high impact on the dependent variable) and ridge regression (i.e., improving of the stability of the estimates).

Thus, the lasso technique is a procedure that penalizes large coefficients by constraining the sum of the absolute coefficients (L1) to equal to or less than an absolute term t. By reducing t, the L1-norm shrinks the same amount. Consequently, dispensable coefficients shrink to zero and are removed from the model. This action leads to the desired selection of variables, but also raises the sums of squares of the residuals.

It is there critical to determine the optimal amount of shrinkage. This can be determined in a ten-fold cross-validation with shrinkage values (s) between 0.0006 and 0.36 in steps of 0.006. Toward this end, the sample was divided into ten subsamples. A regression analysis was performed on one subset and validated on the other nine subsets. To reduce variability, ten rounds of cross-validation were performed using different shrinkage values, and the validation results were averaged over the ten rounds.

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>NC n = 29</th>
<th>AD-P n = 29</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (men/women)</td>
<td>7/15</td>
<td>11/18</td>
</tr>
<tr>
<td>Age (years)</td>
<td>73.5 ± 4.60</td>
<td>73.3 ± 4.63</td>
</tr>
<tr>
<td>Education (years)</td>
<td>12.9 ± 3.33</td>
<td>11.7 ± 3.12</td>
</tr>
<tr>
<td>Mini-Mental Status Examination</td>
<td>28.4 ± 1.52</td>
<td>28.9 ± 1.10</td>
</tr>
<tr>
<td>% ApoE ε4 positive</td>
<td>52%</td>
<td>52%</td>
</tr>
<tr>
<td>Observation period (years)</td>
<td>7.23 ± 1.81</td>
<td>7.91 ± 2.71</td>
</tr>
</tbody>
</table>
RESULTS

For completeness, we summarize the performance of the NC and AD-P groups on each of the 115 cognitive, behavioral, and medical variables in Supplementary Table 2. Since the number of comparisons (k = 115) was larger than the group size, we applied the lasso technique [42]. The optimal CCR was defined as the point at which the corresponding s yielded the best prediction for overall group membership. The highest percentage of correct classification was achieved with a shrinkage of $s = 0.08$, i.e., at 8% of the maximal possible sum of all coefficients. The sum of all coefficients was consequently shrunk by more than 90% and resulted in the correct classification of AD-P and NC in 60.4% of cases (Fig. 1A).

The selection of variables could therefore be determined by constraining the sum of the absolute coefficients to 8% of the maximal possible sum of coefficients (L1), where the maximal possible correct classification of 60.4% was reached. This corresponded to an absolute sum of coefficients of 3.72 (Fig. 1B). Reductions of more than 90% of the maximal possible sum of all coefficients set most of the 115 coefficients to 0, thus dismissing them from the model. However, 11 coefficients were different from 0 at this point, indicating that their corresponding variables predicted group membership of the study samples with the optimal possible correct classification rate.

These regression coefficients (Table 3) show the contribution of each variable to the prediction of group membership (0 = NC, 1 = AD-P), i.e., the probability of being in the AD-P group. Depending on the scale (i.e., low/high score implies better/worse performance or vice versa), coefficients show a corresponding positive or negative amplitude. Odd’s ratios confirmed the strengths each variable’s effect to the prediction of AD-P group membership. The signs of all coefficients are consistent with poorer performance in the AD-P group.

The first variable in the model and thus the variable with the smallest impact on group discrimination was the total score of the Wechsler Adult Intelligence Scale (WAIS) block design, with a coefficient of $b = -0.01$. Thus, AD-P individuals performed worse on this task an average of eight years prior to their diagnosis than those who remain healthy within the same timeframe. The lasso technique further revealed that with increasing L1-norm and simultaneously increasing importance for the model, future AD patients exhibited more repetitions on the phonemic fluency task ($b = 0.03$), a lower total delayed recall score on the CERAD figures task ($b = -0.04$), a lower response bias ($b = -0.08$) on the California Verbal Learning Test (CVLT) recognition test, fewer intrusion errors on the CERAD word-list ($b = -0.11$), a lower score on the WAIS block design items 5 ($b = -0.14$) and 4 ($b = -0.21$), and more errors in on the phonemic fluency task ($b = 0.27$) than matched control peers who maintained...
The eleven variables selected by the lasso analysis best discriminating between normal control participants and individuals who progressed to AD after an average of 8 years. The order of variables corresponds to the order in which they were selected in the lasso analysis (Fig. 1B, from top to bottom). The magnitudes of the coefficients reflect their ability to predict group membership. Odds ratios reflect the strength of variable correlations between groups.

Table 3: Test/Assessment and Coefficient (b) and Odds Rati

<table>
<thead>
<tr>
<th>Test/Assessment</th>
<th>Variable</th>
<th>Coefficient (b)</th>
<th>Odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Memory</td>
<td>Self-reported memory complaints</td>
<td>1.21</td>
<td>3.55</td>
</tr>
<tr>
<td>Medical background</td>
<td>Self-reported current heart problems</td>
<td>0.92</td>
<td>2.52</td>
</tr>
<tr>
<td>Mood changes</td>
<td>Self-reported feeling of sadness</td>
<td>0.68</td>
<td>1.98</td>
</tr>
<tr>
<td>Phonemic Fluency</td>
<td>Errors</td>
<td>0.27</td>
<td>1.31</td>
</tr>
<tr>
<td>Phonemic Fluency</td>
<td>Repetitions</td>
<td>0.03</td>
<td>1.03</td>
</tr>
<tr>
<td>WAIS Block design</td>
<td>Total points</td>
<td>-0.01</td>
<td>0.99</td>
</tr>
<tr>
<td>CERAD Figures</td>
<td>Delayed recall</td>
<td>-0.04</td>
<td>0.96</td>
</tr>
<tr>
<td>CVLT Recognition</td>
<td>Response bias</td>
<td>-0.08</td>
<td>0.92</td>
</tr>
<tr>
<td>CERAD word list</td>
<td>Intrusion errors</td>
<td>-0.11</td>
<td>0.89</td>
</tr>
<tr>
<td>WAIS Block design</td>
<td>Item 5</td>
<td>-0.14</td>
<td>0.87</td>
</tr>
<tr>
<td>WAIS Block design</td>
<td>Item 4</td>
<td>-0.25</td>
<td>0.81</td>
</tr>
</tbody>
</table>

Verbal and visual episodic learning and memory measures were among the best predictors of progression to AD. The order of variables is consistent with previous reports on the predictive utility of quantitative measures of episodic memory function. In contrast to previous models of the evolution of cognitive, clinical, and biomarker changes in AD, we hypothesize that cognitive impairments are not apparent in the preclinical phase preceding mild cognitive impairment (MCI).

**DISCUSSION**

Multiple neuropsychological performance measures significantly predicted progression to AD an average of eight years prior to diagnosis: subjective and objective measures of verbal learning and memory, delayed recall of figural information, the Block Design subtest, numbers of errors and repetitions on letter fluency, as well as self-reported feelings of sadness and cardiac problems. Remarkably, three of the selected predictors are based on self-reports, and three are qualitative in nature. These findings suggest that subjective, qualitative, and quantitative measures of verbal and figural episodic memory performance, visuospatial functioning, frontal lobe function (error control), as well as mild depressive and cardiovascular signs, represent a cluster of symptoms that long antedate the emergence of AD. Notably, these results are inconsistent with recent models of the evolution of cognitive, clinical, and biomarker changes in AD, which hypothesize that cognitive impairments are not apparent in the preclinical phase preceding mild cognitive impairment (MCI).
functioning, as well as qualitative performance measures, which elaborate how participants perform a task, may represent potent measures of the future development of AD.

Visuospatial functioning as measured by the Block Design subtest [48] emerged as a significant predictor of future AD in our data. Similarly, Armaz and colleagues [49] identified the Block Design as the most effective predictor of progression from MCI to AD. According to a new framework [50], visuospatial perceptual processing relies on a dorsal pathway from inferior parietal cortex through the posterior cingulate and retrosplenial cortices on to the parahippocampal cortex and the medial temporal lobe (parieto-medial temporal pathway). Concomitant dysfunction of the medial temporal lobe [13] and posterior cingulate cortex [51] characterize early AD. The present results suggest that medial temporal lobe and/or posterior cingulate cortex dysfunction may surface many years prior to overt AD, potentially disrupting the parieto-medial temporal visuospatial processing pathway, with corresponding impairments reflected in measures such as the Block Design subtest.

Two measures from the letter fluency were selected as discriminators of NC and AD-P participants. We note that the number of errors and repetitions on this task discriminated groups, but not the total number of produced words. Thus, future AD patients demonstrated a failure to inhibit certain responses while searching, accessing and producing words, as opposed to an access or production impairment per se. This pattern indicates a primary dysfunction in orbito-prefrontal rather than medial and dorsolateral prefrontal cortex in the preclinical stage of the disease [52]. The same pattern of normal output with increased number of errors and repetitions has been observed in a comparison of normal control to AD participants [2], although the poor sensitivity of the error measure led Cahn and colleagues [2] to propose that while the presence of errors supported a diagnosis of AD, their absence is of little diagnostic import.

The lasso method selected three additional clinical variables as predictors of future AD. One was subjective memory complaint, which was reported by 17% of future AD patients and none of those who remained healthy. Subjective memory impairment has been found to be a harbinger of further decline in subjects with no cognitive impairment at study entry [31] and has been reported to be an early and strong predictor of AD [32, 53]. Similarly, 17% of AD-P and none of the NC participants reported current cardiac problems. This parallels the widespread finding from several longitudinal studies that cardiovascular function (as measured by objective measures) significantly predicts progression to AD (e.g., [54]). Lastly, a subjective feeling of sadness (FDD [55]) was endorsed by 24% of AD-P compared to 3% of the NC participants. Depressive symptoms that do not even meet criteria for a depressive disorder may be of import. Indeed, the Religious Orders Study [17] reported that the number of depressive symptoms at baseline predicted progression to AD, and that risk for future AD increased by about 20% with each additional symptom of depression (see also [20–30]). It remains unclear whether early depressive symptomatology represents an actual predictor of progression, a prodromal or early manifestation of the disease [30], or a reaction to self-perceived cognitive decline [39]. Taken together, results of these three variables indicate that despite their low specificity, self-reported changes should be carefully considered in conjunction with other objective measures, in clinical practice as well as in research studies on preclinical markers of AD.

Two important limitations of this study are noted. First, all analysis focused on neuropsychological and clinical measures only. While known to contribute to the detection of AD in preclinical stages, biomarkers such as amyloid imaging, cerebrospinal fluid markers, or MRI measures were not available, and their interaction with neuropsychological variables may have improved the present CCR of 60.4%. Second, the relatively small number of participants who developed AD and whose neuropsychological baseline results were available for analysis limits the generalizability of our findings. The relatively small sample size compared to the large number of variables necessitated the use of the lasso technique. The applied L1-penalty favors a regression model with a small number of coefficients that offers a good fit to the data, and allows the reliable selection of variables even from among a large starting set [56]. Thus, the lasso technique provides an elegant statistical solution for studies with comprehensive datasets.

A potentially promising methodological approach for studies of preclinical cognitive changes in AD is the matching of groups according to APOE-status. The lifetime risk of AD at the age of 85 years without reference to APOE genotype is about five-fold lower than that for ApoE4 carriers [57]. Moreover, APOE e4 possession is associated with earlier and faster cognitive decline in patients with AD [58], and may impact cognitive performance, notably episodic memory functions, in cognitively healthy aged persons [59]. APOE-status is therefore a critical selection and
Acknowledgments

We thank the members of the Basel Study on the Elderly (BASEL) for their participation, and the staff of the Memory Clinic of the Department of Geriatrics for their support. This study was supported by grant from the Swiss National Science Foundation (Nr. 3200-049107), the Novartis Foundation, a Swiss National Science Foundation Ambizione Fellowship (to K.I.T.) and the Velux Foundation.


References


Uncorrected Author Proof

N.S. Schmid et al. / Preclinical Markers of Future AD


